Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Lung Neoplasms 1Glioma 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

trametinib 2dabrafenib 2Temozolomide 2Paclitaxel 2Nivolumab 2Carboplatin 2ulixertinib 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1sapanisertib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1erdafitinib 1entinostat 1diazepinomicin 1defactinib 1copanlisib 1cobimetinib 1cediranib 1carboxyamido-triazole 1capivasertib 1cabiralizumab 1binimetinib 1adavosertib 1X-Rays 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × diazepinomicin × Gynecologic × Clear all
NCT00338026 2008-07-15

A Phase I Study of ECO-4601 in Patients With Advanced Cancer

Thallion Pharmaceuticals

Phase 1 Completed
26 enrolled
BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Glioma, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡